D. R. Abernethy, Development of Memory-Enhancing Agents in the Treatment of Alzheimer's Disease, Journal of the American Geriatrics Society, vol.37, issue.10, pp.957-958, 1987.
DOI : 10.1038/clpt.1985.54

E. L. Abner, F. A. Schmitt, P. T. Nelson, W. Lou, L. Wan et al., The Statistical Modeling of Aging and Risk of Transition Project: Data Collection and Harmonization Across 11 Longitudinal Cohort Studies of Aging, Cognition, and Dementia, Obs. Stud, vol.1, pp.56-73, 2015.

P. R. Albert, L. François, B. Millar, and A. M. , Transcriptional dysregulation of 5-HT1A autoreceptors in mental illness, Molecular Brain, vol.4, issue.1, 2011.
DOI : 10.1523/JNEUROSCI.2409-10.2010

P. Allain, F. Etcharry-bouyx, and C. Verny, Executive functions in clinical and preclinical Alzheimer's disease, Revue Neurologique, vol.169, issue.10, pp.695-708, 2013.
DOI : 10.1016/j.neurol.2013.07.020

M. L. Alosco, H. , and S. M. , Structural brain alterations in heart failure: a review of the literature and implications for risk of Alzheimer???s disease, Heart Failure Reviews, vol.2013, issue.8, pp.561-571, 2015.
DOI : 10.1093/brain/awp105

A. Alzheimer, R. A. Stelzmann, H. N. Schnitzlein, and F. R. Murtagh, An English translation of Alzheimer's 1907 paper Clin, 1995.

O. Ambrée, H. Richter, N. Sachser, L. Lewejohann, E. Dere et al., Levodopa ameliorates learning and memory deficits in a murine model of Alzheimer???s disease, Neurobiology of Aging, vol.30, issue.8, pp.1192-1204, 2009.
DOI : 10.1016/j.neurobiolaging.2007.11.010

C. Annweiler, B. Brugg, J. Peyrin, R. Bartha, and O. Beauchet, Combination of memantine and vitamin D prevents axon degeneration induced by amyloid-beta and glutamate, Neurobiology of Aging, vol.35, issue.2, pp.331-335, 2014.
DOI : 10.1016/j.neurobiolaging.2013.07.029

URL : https://hal.archives-ouvertes.fr/hal-01544168

T. Arendt, Synaptic degeneration in Alzheimer???s disease, Acta Neuropathologica, vol.145, issue.2, pp.167-179, 2009.
DOI : 10.1001/archneur.1994.00540200048015

T. Arendt, J. Stieler, and M. Holzer, Tau and tauopathies, Brain Research Bulletin, vol.126, 2016.
DOI : 10.1016/j.brainresbull.2016.08.018

K. F. Bell, L. Zheng, F. Fahrenholz, and A. C. Cuello, ADAM-10 over-expression increases cortical synaptogenesis, Neurobiology of Aging, vol.29, issue.4, pp.554-565, 2008.
DOI : 10.1016/j.neurobiolaging.2006.11.004

S. Belleville, C. Fouquet, S. Duchesne, D. L. Collins, and C. Hudon, Detecting early preclinical Alzheimer's disease via cognition, neuropsychiatry, and neuroimaging: qualitative review and recommendations for testing, J. Alzheimers Dis. JAD, vol.42, pp.375-382, 2014.

F. Belluti, A. De-simone, A. Tarozzi, M. Bartolini, A. Djemil et al., Fluorinated benzophenone derivatives: Balanced multipotent agents for Alzheimer's disease, European Journal of Medicinal Chemistry, vol.78, pp.157-166, 2014.
DOI : 10.1016/j.ejmech.2014.03.042

S. Bhattacharya, C. Haertel, A. Maelicke, and D. Montag, Galantamine Slows Down Plaque Formation and Behavioral Decline in the 5XFAD Mouse Model of Alzheimer???s Disease, PLoS ONE, vol.40, issue.2, p.89454, 2014.
DOI : 10.1371/journal.pone.0089454.g007

S. Billioti-de-gage, Y. Moride, T. Ducruet, T. Kurth, H. Verdoux et al., Benzodiazepine use and risk of Alzheimer's disease: case-control study, BMJ, vol.349, issue.sep09 2, p.5205, 2014.
DOI : 10.1136/bmj.g5205

J. Bockaert, M. Sebben, and A. Dumuis, Pharmacological characterization of 5- hydroxytryptamine4(5-HT4) receptors positively coupled to adenylate cyclase in adult guinea pig hippocampal membranes: effect of substituted benzamide derivatives, Mol. Pharmacol, vol.37, pp.408-411, 1990.

J. Bockaert, S. Claeysen, V. Compan, and A. Dumuis, 5-HT4 receptors: History, molecular pharmacology and brain functions, Neuropharmacology, vol.55, issue.6, pp.922-931, 2008.
DOI : 10.1016/j.neuropharm.2008.05.013

A. Breining, D. Bonnet-zamponi, L. Zerah, C. Micheneau, N. Riolacci-dhoyen et al., Exposure to psychotropics in the French older population living with dementia: a nationwide population-based study, International Journal of Geriatric Psychiatry, vol.169, issue.180, 2016.
DOI : 10.1001/archinternmed.2009.357

URL : https://hal.archives-ouvertes.fr/hal-01545499

A. M. Brickman and Y. Stern, Aging and Memory in Humans, Encyclopedia of Neuroscience, pp.175-180, 2009.
DOI : 10.1016/B978-008045046-9.00745-2

J. Bright, S. Hussain, V. Dang, S. Wright, B. Cooper et al., Human secreted tau increases amyloid-beta production, Neurobiology of Aging, vol.36, issue.2, pp.693-709, 2015.
DOI : 10.1016/j.neurobiolaging.2014.09.007

URL : http://doi.org/10.1016/j.neurobiolaging.2014.09.007

R. F. De-bruijn and M. A. Ikram, Cardiovascular risk factors and future risk of Alzheimer???s disease, BMC Medicine, vol.53, issue.1, p.130, 2014.
DOI : 10.1046/j.1365-2265.2000.01146.x

D. Bruin, N. M. Prickaerts, J. Van-loevezijn, A. Venhorst, J. De-groote et al., Two novel 5-HT6 receptor antagonists ameliorate scopolamine-induced memory deficits in the object recognition and object location tasks in Wistar rats, Neurobiology of Learning and Memory, vol.96, issue.2, pp.392-402, 2011.
DOI : 10.1016/j.nlm.2011.06.015

Y. Buskila, S. E. Crowe, E. , and G. C. , Synaptic deficits in layer 5 neurons precede overt structural decay in 5xFAD mice, Neuroscience, vol.254, pp.152-159, 2013.
DOI : 10.1016/j.neuroscience.2013.09.016

M. Cachard-chastel, F. Lezoualc-'h, I. Dewachter, C. Deloménie, S. Croes et al., receptor agonists increase sAPP?? levels in the cortex and hippocampus of male C57BL/6j mice, British Journal of Pharmacology, vol.90, issue.7, pp.883-892, 2007.
DOI : 10.3748/wjg.v9.i9.2065

M. Cachard-chastel, S. Devers, S. Sicsic, M. Langlois, F. Lezoualc-'h et al., Prucalopride and donepezil act synergistically to reverse scopolamine-induced memory deficit in C57Bl/6j mice, Behavioural Brain Research, vol.187, issue.2, pp.455-461, 2008.
DOI : 10.1016/j.bbr.2007.10.008

C. Campos, N. B. Rocha, R. T. Vieira, S. A. Rocha, D. Telles-correia et al., Treatment of Cognitive Deficits in Alzheimer's disease: A psychopharmacological review, Psychiatr. Danub, vol.28, pp.2-12, 2016.

F. J. Carvajal and N. C. Inestrosa, Interactions of AChE with A? Aggregates in Alzheimer's Brain: Therapeutic Relevance of IDN 5706, Front. Mol. Neurosci, vol.4, 2011.

R. J. Castellani, R. K. Rolston, and M. A. Smith, Alzheimer Disease, Disease-a-Month, vol.56, issue.9, pp.484-546, 2010.
DOI : 10.1016/j.disamonth.2010.06.001

L. Cheewakriengkrai and S. Gauthier, A 10-year perspective on donepezil, Expert Opinion on Pharmacotherapy, vol.39, issue.5, pp.331-338, 2013.
DOI : 10.1002/gps.811

K. H. Chen, E. A. Reese, H. Kim, S. I. Rapoport, and J. S. Rao, Disturbed Neurotransmitter Transporter Expression in Alzheimer???s Disease Brain, Journal of Alzheimer's Disease, vol.26, issue.4, pp.755-766, 2011.
DOI : 10.3233/JAD-2011-110002

F. Chersi and N. Burgess, The Cognitive Architecture of Spatial Navigation: Hippocampal and Striatal Contributions, Neuron, vol.88, issue.1, pp.64-77, 2015.
DOI : 10.1016/j.neuron.2015.09.021

V. Chouraki and S. Seshadri, Genetics of Alzheimer???s Disease, Adv. Genet, vol.87, pp.245-294, 2014.
DOI : 10.1016/B978-0-12-800149-3.00005-6

Y. Chudasama and T. W. Robbins, Dopaminergic Modulation of Visual Attention and Working Memory in the Rodent Prefrontal Cortex, Neuropsychopharmacology, vol.29, issue.9, pp.1628-1636, 2004.
DOI : 10.1038/sj.npp.1300490

I. Chumakov, S. Nabirotchkin, N. Cholet, A. Milet, A. Boucard et al., Combining two repurposed drugs as a promising approach for Alzheimer's disease therapy, Scientific Reports, vol.3, issue.2, p.7608, 2015.
DOI : 10.1124/jpet.106.104117

D. Ciavardelli, F. Piras, A. Consalvo, C. Rossi, M. Zucchelli et al., Medium-chain plasma acylcarnitines, ketone levels, cognition, and gray matter volumes in healthy elderly, mildly cognitively impaired, or Alzheimer's disease subjects, Neurobiology of Aging, vol.43, pp.1-12, 2016.
DOI : 10.1016/j.neurobiolaging.2016.03.005

J. R. Cirrito, R. Deane, A. M. Fagan, M. L. Spinner, M. Parsadanian et al., P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model, J. Clin, 2005.

S. Claeysen, P. Faye, M. Sebben, S. Taviaux, J. Bockaert et al., 5-HT4 Receptors: Cloning and Expression of New Splice Variants, Annals of the New York Academy of Sciences, vol.87, issue.1 ADVANCES IN S, pp.49-56, 1998.
DOI : 10.1016/S0165-6147(00)89081-1

S. Claeysen, M. Sebben, C. Becamel, J. Bockaert, and A. Dumuis, Novel brainspecific 5-HT4 receptor splice variants show marked constitutive activity: role of the Cterminal intracellular domain, Mol. Pharmacol, vol.55, pp.910-920, 1999.

T. A. Clark, H. P. Lee, R. K. Rolston, X. Zhu, M. W. Marlatt et al., Oxidative Stress and its Implications for Future Treatments and Management of Alzheimer Disease, Int. J. Biomed. Sci. IJBS, vol.6, pp.225-227, 2010.

M. Cochet, R. Donneger, E. Cassier, F. Gaven, S. F. Lichtenthaler et al., Receptors Constitutively Promote the Non-Amyloidogenic Pathway of APP Cleavage and Interact with ADAM10, ACS Chemical Neuroscience, vol.4, issue.1, pp.130-140, 2013.
DOI : 10.1021/cn300095t

F. Corrigan, R. Vink, P. C. Blumbergs, C. L. Masters, R. Cappai et al., Evaluation of the effects of treatment with sAPP?? on functional and histological outcome following controlled cortical impact injury in mice, Neuroscience Letters, vol.515, issue.1, pp.50-54, 2012.
DOI : 10.1016/j.neulet.2012.03.017

B. Costall, B. J. Jones, M. E. Kelly, R. J. Naylor, and D. M. Tomkins, Exploration of mice in a black and white test box: Validation as a model of anxiety, Pharmacology Biochemistry and Behavior, vol.32, issue.3, pp.777-785, 1989.
DOI : 10.1016/0091-3057(89)90033-6

S. T. Creavin, S. Wisniewski, A. H. Noel-storr, C. M. Trevelyan, T. Hampton et al., Mini-Mental State Examination (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and over in community and primary care populations, Cochrane Database Syst. Rev, vol.21, issue.1, p.11145, 2016.
DOI : 10.1017/S0033291700014811

M. L. Crismon, Tacrine: First Drug Approved for Alzheimer's Disease, Annals of Pharmacotherapy, vol.160, issue.6, pp.744-751, 1994.
DOI : 10.1192/bjp.160.1.36

S. Cunnane, S. Nugent, M. Roy, A. Courchesne-loyer, E. Croteau et al., Brain fuel metabolism, aging, and Alzheimer's disease. Nutr, Cty. Calif, vol.27, pp.3-20, 2011.

W. Danysz and C. G. Parsons, The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence, International Journal of Geriatric Psychiatry, vol.296, issue.S1, pp.23-32, 2003.
DOI : 10.1001/archneur.1986.00520100062016

F. Darcet, A. M. Gardier, D. J. David, and J. Guilloux, Chronic 5-HT4 receptor agonist treatment restores learning and memory deficits in a neuroendocrine mouse model of anxiety/depression, Neuroscience Letters, vol.616, pp.197-203, 2016.
DOI : 10.1016/j.neulet.2016.01.055

L. A. Dawson, H. Q. Nguyen, L. , and P. , antagonist SB-271046 on striatal and frontal cortex extracellular concentrations of noradrenaline, dopamine, 5-HT, glutamate and aspartate, British Journal of Pharmacology, vol.64, issue.1, pp.23-26, 2000.
DOI : 10.1038/sj.bjp.0703288

C. Decarli, Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment, The Lancet Neurology, vol.2, issue.1, pp.15-21, 2003.
DOI : 10.1016/S1474-4422(03)00262-X

A. R. Deipolyi, K. P. Rankin, L. Mucke, B. L. Miller, and M. L. Gorno-tempini, Spatial cognition and the human navigation network in AD and MCI, Neurology, vol.69, issue.10, pp.986-997, 2007.
DOI : 10.1212/01.wnl.0000271376.19515.c6

J. Deng, A. Habib, D. F. Obregon, S. W. Barger, B. Giunta et al., Soluble amyloid precursor protein alpha inhibits tau phosphorylation through modulation of GSK3?? signaling pathway, Journal of Neurochemistry, vol.31, issue.3, pp.630-637, 2015.
DOI : 10.1523/JNEUROSCI.3268-10.2011

L. Deuker, J. L. Bellmund, T. Navarro-schröder, and C. F. Doeller, Author response image 1. Effects are preserved across different searchlight sizes., eLife, vol.75, 2016.
DOI : 10.7554/eLife.16534.016

J. F. Diedrich, H. Minnigan, R. I. Carp, J. N. Whitaker, R. Race et al., Neuropathological changes in scrapie and Alzheimer's disease are associated with increased expression of apolipoprotein E and cathepsin D in astrocytes, J. Virol, vol.65, pp.4759-4768, 1991.

M. C. Dinamarca, W. Cerpa, J. Garrido, J. L. Hancke, and N. C. Inestrosa, Hyperforin prevents ??-amyloid neurotoxicity and spatial memory impairments by disaggregation of Alzheimer's amyloid-??-deposits, Molecular Psychiatry, vol.5, issue.11, pp.1032-1048, 2006.
DOI : 10.1073/pnas.182425199

S. Dogra, Y. , and P. N. , Biased agonism at kappa opioid receptors: Implication in pain and mood disorders, European Journal of Pharmacology, vol.763, pp.184-190, 2015.
DOI : 10.1016/j.ejphar.2015.07.018

P. M. Doraiswamy, Non-Cholinergic Strategies for Treating and Preventing Alzheimer??s Disease, CNS Drugs, vol.19, issue.1, pp.811-824, 2002.
DOI : 10.2165/00023210-200216120-00003

P. M. Doraiswamy, The role of the N-methyl-D-aspartate receptor in Alzheimer???s disease: Therapeutic potential, Current Neurology and Neuroscience Reports, vol.306, issue.suppl, pp.373-378, 2003.
DOI : 10.1161/01.STR.26.4.602

A. Dumuis, R. Bouhelal, M. Sebben, R. Cory, and J. Bockaert, A nonclassical 5- hydroxytryptamine receptor positively coupled with adenylate cyclase in the central nervous system, Mol. Pharmacol, vol.34, pp.880-887, 1988.

T. Dyrks, A. Weidemann, G. Multhaup, J. M. Salbaum, H. G. Lemaire et al., Identification, transmembrane orientation and biogenesis of the amyloid A4 precursor of Alzheimer's disease, EMBO J, vol.7, pp.949-957, 1988.

M. W. Dysken, M. Sano, S. Asthana, J. E. Vertrees, M. Pallaki et al., Effect of Vitamin E and Memantine on Functional Decline in Alzheimer Disease, JAMA, vol.311, issue.1, pp.33-44, 2014.
DOI : 10.1001/jama.2013.282834

E. C. Edmonds, L. Delano-wood, D. R. Galasko, D. P. Salmon, M. W. Bondi et al., Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer???s Disease, Disease Neuroimaging Initiative, pp.231-242, 2015.
DOI : 10.1017/S1355617708080387

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4634634

F. S. Esch, P. S. Keim, E. C. Beattie, R. W. Blacher, A. R. Culwell et al., Cleavage of amyloid beta peptide during constitutive processing of its precursor, Science, vol.248, issue.4959, pp.1122-1124, 1990.
DOI : 10.1126/science.2111583

S. Estus, T. E. Golde, T. Kunishita, D. Blades, D. Lowery et al., Potentially amyloidogenic, carboxyl-terminal derivatives of the amyloid protein precursor, Science, vol.255, issue.5045, pp.726-728, 1992.
DOI : 10.1126/science.1738846

D. A. Evans, L. E. Hebert, L. A. Beckett, P. A. Scherr, M. S. Albert et al., Education and Other Measures of Socioeconomic Status and Risk of Incident Alzheimer Disease in a Defined Population of Older Persons, Archives of Neurology, vol.54, issue.11, pp.1399-1405, 1997.
DOI : 10.1001/archneur.1997.00550230066019

M. Farokhnia, S. Sabet, M. Iranpour, N. Gougol, A. Yekehtaz et al., L. with memantine in patients with moderate to severe Alzheimer's disease: a double-blind randomized clinical trial, Human Psychopharmacology: Clinical and Experimental, vol.8, issue.Suppl 1, pp.351-359, 2014.
DOI : 10.1186/1472-6963-8-108

I. L. Ferreira, R. Resende, E. Ferreiro, A. C. Rego, and C. F. Pereira, Multiple Defects in Energy Metabolism in Alzheimers Disease, Current Drug Targets, vol.11, issue.10, pp.1193-1206, 2010.
DOI : 10.2174/1389450111007011193

S. H. Ferris and M. Farlow, Language impairment in Alzheimer's disease and benefits of acetylcholinesterase inhibitors, Clin. Interv. Aging, vol.8, pp.1007-1014, 2013.

A. G. Foley, K. J. Murphy, W. D. Hirst, H. C. Gallagher, J. J. Hagan et al., The 5-HT6 Receptor Antagonist SB-271046 Reverses Scopolamine-Disrupted Consolidation of a Passive Avoidance Task and Ameliorates Spatial Task Deficits in Aged Rats, Neuropsychopharmacology, vol.29, issue.1, pp.93-100, 2004.
DOI : 10.1038/sj.npp.1300332

L. Fratiglioni, D. De-ronchi, and H. Agüero-torres, Worldwide Prevalence and Incidence of Dementia, Drugs & Aging, vol.15, issue.5, pp.365-375, 1999.
DOI : 10.2165/00002512-199915050-00004

R. P. Friedland, T. Fritsch, K. A. Smyth, E. Koss, A. J. Lerner et al., Patients with Alzheimer's disease have reduced activities in midlife compared with healthy control-group members, Proc. Natl. Acad. Sci. U. S. A. 98, pp.3440-3445, 2001.
DOI : 10.1176/ajp.152.10.1485

K. Furukawa, B. L. Sopher, R. E. Rydel, J. G. Begley, D. G. Pham et al., Increased Activity-Regulating and Neuroprotective Efficacy of ??-Secretase-Derived Secreted Amyloid Precursor Protein Conferred by a C-Terminal Heparin-Binding Domain, Journal of Neurochemistry, vol.67, issue.5, pp.1882-1896, 1996.
DOI : 10.1046/j.1471-4159.1996.67051882.x

S. Gao, H. C. Hendrie, K. S. Hall, H. , and S. , The Relationships Between Age, Sex, and the Incidence of Dementia and Alzheimer Disease, Archives of General Psychiatry, vol.55, issue.9, pp.809-815, 1998.
DOI : 10.1001/archpsyc.55.9.809

M. L. Garcez, A. C. Falchetti, F. Mina, and J. Budni, Alzheimer??s Disease associated with Psychiatric Comorbidities, Anais da Academia Brasileira de Ci??ncias, vol.11, issue.Suppl 1, pp.1461-1473, 2015.
DOI : 10.2174/1567205011666140812115004

URL : http://doi.org/10.1590/0001-3765201520140716

C. Gerald, N. Adham, H. T. Kao, M. A. Olsen, T. M. Laz et al., The 5-HT4 receptor: molecular cloning and pharmacological characterization of two splice variants, EMBO J, vol.14, pp.2806-2815, 1995.

C. Germano and G. J. Kinsella, Working Memory and Learning in Early Alzheimer?s Disease, Neuropsychology Review, vol.5, issue.1, pp.1-10, 2005.
DOI : 10.1111/j.1532-5415.1992.tb01992.x

P. Giannoni, F. Gaven, D. De-bundel, K. Baranger, E. Marchetti-gauthier et al., Early administration of RS 67333, a specific 5-HT4 receptor agonist, prevents amyloidogenesis and behavioral deficits in the 5XFAD mouse model of Alzheimer???s disease, Frontiers in Aging Neuroscience, vol.5, p.96, 2013.
DOI : 10.3389/fnagi.2013.00096

S. Gillette-guyonnet, S. Andrieu, F. Nourhashemi, V. Gardette, N. Coley et al., Long-term progression of Alzheimer???s disease in patients under antidementia drugs, Alzheimer's & Dementia, vol.7, issue.6, 2011.
DOI : 10.1016/j.jalz.2011.02.009

G. G. Glenner and C. W. Wong, Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein, Biochemical and Biophysical Research Communications, vol.120, issue.3, pp.885-890, 1984.
DOI : 10.1016/S0006-291X(84)80190-4

J. Gody?, J. Jo?czyk, D. Panek, and B. Malawska, Therapeutic strategies for Alzheimer's disease in clinical trials, Pharmacological Reports, vol.68, issue.1, pp.127-138, 2016.
DOI : 10.1016/j.pharep.2015.07.006

M. Goedert, Neuronal localization of amyloid beta protein precursor mRNA in normal human brain and in Alzheimer's disease, EMBO J, vol.6, pp.3627-3632, 1987.

F. Gosselet, P. Candela, R. Cecchelli, and L. Fenart, [Role of the blood-brain barrier in Alzheimer's disease], Med. Sci. MS, vol.27, pp.987-992, 2011.

S. L. Gray, S. Dublin, O. Yu, R. Walker, M. Anderson et al., Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study, BMJ, vol.352, p.90, 2016.
DOI : 10.1136/bmj.i90

M. Grimaldi, S. D. Marino, F. Florenzano, M. T. Ciotta, S. L. Nori et al., ??-Amyloid-acetylcholine molecular interaction: new role of cholinergic mediators in anti-Alzheimer therapy?, Future Medicinal Chemistry, vol.8, issue.11, pp.1179-1189, 2016.
DOI : 10.4155/fmc-2016-0006

A. Habib, D. Sawmiller, and J. Tan, Restoring Soluble Amyloid Precursor Protein ?? Functions as a Potential Treatment for Alzheimer's Disease, Journal of Neuroscience Research, vol.368, issue.Suppl 2, 2016.
DOI : 10.1038/368635a0

N. Hasebe, Y. Fujita, M. Ueno, K. Yoshimura, Y. Fujino et al., Soluble ?amyloid Precursor Protein Alpha binds to p75 neurotrophin receptor to promote neurite outgrowth, PloS One, vol.8, 2013.

M. Hasegawa, Molecular Mechanisms in the Pathogenesis of Alzheimer???s disease and Tauopathies-Prion-Like Seeded Aggregation and Phosphorylation, Biomolecules, vol.44, issue.2, 2016.
DOI : 10.1038/nrd4179

G. Hashimoto, M. Sakurai, A. F. Teich, F. Saeed, F. Aziz et al., 5-HT? receptor stimulation leads to soluble A?PP? production through MMP-9 upregulation, J. Alzheimers Dis. JAD, vol.32, pp.437-445, 2012.

S. G. Haskell, E. D. Richardson, and R. I. Horwitz, The effect of estrogen replacement therapy on cognitive function in women: A critical review of the literature, Journal of Clinical Epidemiology, vol.50, issue.11, pp.1249-1264, 1997.
DOI : 10.1016/S0895-4356(97)00169-8

L. B. Hassing, B. Johansson, S. E. Nilsson, S. Berg, N. L. Pedersen et al., Diabetes Mellitus Is a Risk Factor for Vascular Dementia, but Not for Alzheimers Disease: A Population-Based Study of the Oldest Old, International Psychogeriatrics, vol.14, issue.3, pp.239-248, 2002.
DOI : 10.1017/S104161020200844X

L. Helboe, J. Egebjerg, and I. E. De-jong, Distribution of serotonin receptor 5-HT6 mRNA in rat neuronal subpopulations: A double in situ hybridization study, Neuroscience, vol.310, pp.442-454, 2015.
DOI : 10.1016/j.neuroscience.2015.09.064

V. W. Henderson, W. Mack, W. , and B. W. , Spatial Disorientation in Alzheimer's Disease, Archives of Neurology, vol.46, issue.4, pp.391-394, 1989.
DOI : 10.1001/archneur.1989.00520400045018

C. Héraud, D. Goufak, K. Ando, K. Leroy, V. Suain et al., Increased misfolding and truncation of tau in APP/PS1/tau transgenic mice compared to mutant tau mice, Neurobiology of Disease, vol.62, pp.100-112, 2014.
DOI : 10.1016/j.nbd.2013.09.010

G. A. Higgins, D. A. Lewis, S. Bahmanyar, D. Goldgaber, D. C. Gajdusek et al., Differential regulation of amyloid-beta-protein mRNA expression within hippocampal neuronal subpopulations in Alzheimer disease., Proceedings of the National Academy of Sciences, vol.85, issue.4, pp.1297-1301, 1988.
DOI : 10.1073/pnas.85.4.1297

K. L. Hildreth and S. Church, Evaluation and Management of the Elderly Patient Presenting with Cognitive Complaints, Medical Clinics of North America, vol.99, issue.2, pp.311-335, 2015.
DOI : 10.1016/j.mcna.2014.11.006

W. D. Hirst, B. Abrahamsen, F. E. Blaney, A. R. Calver, L. Aloj et al., Differences in the Central Nervous System Distribution and Pharmacology of the Mouse 5-Hydroxytryptamine-6 Receptor Compared with Rat and Human Receptors Investigated by Radioligand Binding, Site-Directed Mutagenesis, and Molecular Modeling, Molecular Pharmacology, vol.64, issue.6, pp.1295-1308, 2003.
DOI : 10.1124/mol.64.6.1295

C. Hölscher, Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease, Biochemical Society Transactions, vol.23, issue.4, pp.891-897, 2011.
DOI : 10.1006/bbrc.2000.3763

L. Huang, X. Su, and H. J. Federoff, Single-Chain Fragment Variable Passive Immunotherapies for Neurodegenerative Diseases, International Journal of Molecular Sciences, vol.7, issue.9, pp.19109-19127, 2013.
DOI : 10.1038/nchembio.582

URL : http://doi.org/10.3390/ijms140919109

P. Imfeld, M. Bodmer, S. S. Jick, M. , and C. R. , Benzodiazepine Use and Risk of Developing Alzheimer???s Disease or Vascular Dementia: A Case???Control Analysis, Drug Safety, vol.3, issue.10, pp.909-919, 2015.
DOI : 10.1517/14740338.3.5.485

C. R. Jack, D. S. Knopman, W. J. Jagust, R. C. Petersen, M. W. Weiner et al., Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers, The Lancet Neurology, vol.12, issue.2, pp.207-216, 2013.
DOI : 10.1016/S1474-4422(12)70291-0

J. Jacobs, J. Miller, S. A. Lee, T. Coffey, A. J. Watrous et al., Direct Electrical Stimulation of the Human Entorhinal Region and Hippocampus Impairs Memory, Neuron, vol.92, issue.5, pp.983-990, 2016.
DOI : 10.1016/j.neuron.2016.10.062

H. Jahn, Memory loss in Alzheimer's disease, Dialogues Clin. Neurosci, vol.15, pp.445-454, 2013.

J. T. Jarrett, E. P. Berger, and P. T. Lansbury, The C-Terminus of the ?? Protein is Critical in Amyloidogenesisa, Annals of the New York Academy of Sciences, vol.30, issue.1, pp.144-148, 1993.
DOI : 10.1021/bi00107a004

A. L. Jefferson, A. S. Beiser, J. J. Himali, S. Seshadri, C. J. O-'donnell et al., Low Cardiac Index Is Associated With Incident Dementia and Alzheimer Disease: The Framingham Heart Study, Circulation, vol.131, issue.15, pp.1333-1339, 2015.
DOI : 10.1161/CIRCULATIONAHA.114.012438

V. Jelic and B. Winblad, Alzheimer disease: Donepezil and nursing home placement ??? benefits and costs, Nature Reviews Neurology, vol.29, issue.1, pp.11-13, 2016.
DOI : 10.1007/s40266-012-0002-7

S. Jiang, Y. Li, C. Zhang, Y. Zhao, G. Bu et al., M1 muscarinic acetylcholine receptor in Alzheimer???s disease, Neuroscience Bulletin, vol.1, issue.Suppl4, pp.295-307, 2014.
DOI : 10.1021/cn900003h

P. Jin, J. Kim, D. Choi, Y. Lee, H. S. Jung et al., Anti-inflammatory and anti-amyloidogenic effects of a small moleculebis(p-hydroxyphenyl)-2-butenal in Tg2576 Alzheimer's disease mice model, J. Neuroinflammation, vol.2, issue.10 2, 2013.

D. E. Johnson, E. Drummond, S. Grimwood, A. Sawant-basak, E. Miller et al., The 5-Hydroxytryptamine4 Receptor Agonists Prucalopride and PRX-03140 Increase Acetylcholine and Histamine Levels in the Rat Prefrontal Cortex and the Power of Stimulated Hippocampal ?? Oscillations, Journal of Pharmacology and Experimental Therapeutics, vol.341, issue.3, pp.681-691, 2012.
DOI : 10.1124/jpet.112.192351

Z. Jun, M. M. Ibrahim, G. Dezheng, Y. Bo, W. Qiong et al., UCP2 protects against amyloid beta toxicity and oxidative stress in primary neuronal culture, Biomedicine & Pharmacotherapy, vol.74, pp.211-214, 2015.
DOI : 10.1016/j.biopha.2015.08.001

J. Kang, H. G. Lemaire, A. Unterbeck, J. M. Salbaum, C. L. Masters et al., The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor, Nature, vol.325, issue.6106, pp.733-736, 1987.
DOI : 10.1038/325733a0

I. Kendall, H. A. Slotten, X. Codony, J. Burgueño, P. J. Pauwels et al., E-6801, a 5-HT6 receptor agonist, improves recognition memory by combined modulation of cholinergic and glutamatergic neurotransmission in the rat, Psychopharmacology, vol.85, issue.2-3, pp.413-430, 2011.
DOI : 10.1016/j.pbb.2006.08.011

S. Kim, M. J. Kim, S. Kim, H. S. Kang, S. W. Lim et al., Gender differences in risk factors for transition from mild cognitive impairment to Alzheimer???s disease: A CREDOS study, Comprehensive Psychiatry, vol.62, pp.114-122, 2015.
DOI : 10.1016/j.comppsych.2015.07.002

T. Kim, C. Pae, S. Yoon, W. Jang, N. J. Lee et al., Decreased plasma antioxidants in patients with Alzheimer's disease, International Journal of Geriatric Psychiatry, vol.3, issue.4, 2006.
DOI : 10.1016/0304-4165(87)90155-3

A. M. Klein, N. W. Kowall, and R. J. Ferrante, Neurotoxicity and Oxidative Damage of Beta Amyloid 1-42 versus Beta Amyloid 1-40 in the Mouse Cerebral Cortex, Annals of the New York Academy of Sciences, vol.826, issue.4, 1999.
DOI : 10.1016/S0006-8993(97)00383-1

I. Klinkenberg and A. Blokland, The validity of scopolamine as a pharmacological model for cognitive impairment: A review of animal behavioral studies, Neuroscience & Biobehavioral Reviews, vol.34, issue.8, pp.1307-1350, 2010.
DOI : 10.1016/j.neubiorev.2010.04.001

M. J. Knight, B. Mccann, R. A. Kauppinen, C. , and E. J. , Magnetic Resonance Imaging to Detect Early Molecular and Cellular Changes in Alzheimer's Disease. Front, Aging Neurosci, vol.8, p.139, 2016.

J. D. Koen, Y. , and A. P. , The Effects of Healthy Aging, Amnestic Mild Cognitive Impairment, and Alzheimer???s Disease on Recollection and Familiarity: A Meta-Analytic Review, Neuropsychology Review, vol.20, issue.11, pp.332-354, 2014.
DOI : 10.1002/hipo.20864

F. C. Lam, R. Liu, P. Lu, A. B. Shapiro, J. M. Renoir et al., ??-Amyloid efflux mediated by p-glycoprotein, Journal of Neurochemistry, vol.2, issue.4, pp.1121-1128, 2001.
DOI : 10.1042/bj3330621

L. Lamirault and H. Simon, Enhancement of place and object recognition memory in young adult and old rats by RS 67333, a partial agonist of 5-HT4 receptors, Neuropharmacology, vol.41, issue.7, pp.844-853, 2001.
DOI : 10.1016/S0028-3908(01)00123-X

S. Lammich, E. Kojro, R. Postina, S. Gilbert, R. Pfeiffer et al., Constitutive and regulated ??-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease, Proceedings of the National Academy of Sciences, vol.273, issue.48, pp.3922-3927, 1999.
DOI : 10.1074/jbc.273.48.31648

J. Lan, S. Xie, S. Li, L. Pan, X. Wang et al., Design, synthesis and evaluation of novel tacrine-(??-carboline) hybrids as multifunctional agents for the treatment of Alzheimer???s disease, Bioorganic & Medicinal Chemistry, vol.22, issue.21, 2014.
DOI : 10.1016/j.bmc.2014.08.035

K. Laver, S. Dyer, C. Whitehead, L. Clemson, and M. Crotty, Interventions to delay functional decline in people with dementia: a systematic review of systematic reviews, BMJ Open, vol.28, issue.(2), 2016.
DOI : 10.1002/gps.3864

C. Lecoutey, D. Hedou, T. Freret, P. Giannoni, F. Gaven et al., Design of donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor with potential interest for Alzheimer's disease treatment, Proc. Natl. Acad. Sci. U. S. A. 111, pp.3825-3830, 2014.
DOI : 10.1016/0006-2952(61)90145-9

V. Lelong, L. Lhonneur, F. Dauphin, and M. Boulouard, BIMU 1 and RS 67333, two 5-HT4 receptor agonists, modulate spontaneous alternation deficits induced by scopolamine in the mouse, Naunyn-Schmiedeberg's Archives of Pharmacology, vol.367, issue.6, pp.621-628, 2003.
DOI : 10.1007/s00210-003-0743-2

J. Lewerenz and P. Maher, Chronic Glutamate Toxicity in Neurodegenerative Diseases???What is the Evidence?, Frontiers in Neuroscience, vol.145, issue.165, p.469, 2015.
DOI : 10.1016/j.cell.2011.05.020

G. Li, J. Klein, and M. Zimmermann, Pathophysiological amyloid concentrations induce sustained upregulation of readthrough acetylcholinesterase mediating anti-apoptotic effects, Neuroscience, vol.240, pp.349-360, 2013.
DOI : 10.1016/j.neuroscience.2013.02.040

M. M. Lim, J. R. Gerstner, and D. M. Holtzman, The sleep???wake cycle and Alzheimer's disease: what do we know?, Neurodegenerative Disease Management, vol.4, issue.5, pp.351-362, 2014.
DOI : 10.2217/nmt.14.33

H. Liu, X. Liu, H. Fan, J. Tang, X. Gao et al., Design, synthesis and pharmacological evaluation of chalcone derivatives as acetylcholinesterase inhibitors, Bioorganic & Medicinal Chemistry, vol.22, issue.21, 2014.
DOI : 10.1016/j.bmc.2014.08.033

M. Liu, M. S. Geddis, Y. Wen, W. Setlik, G. et al., Expression and function of 5-HT4 receptors in the mouse enteric nervous system, AJP: Gastrointestinal and Liver Physiology, vol.289, issue.6, pp.1148-1163, 2005.
DOI : 10.1152/ajpgi.00245.2005

T. Liu, Z. Xia, W. Zhang, J. Xu, X. Ge et al., Bis(9)-(???)-nor-meptazinol as a novel dual-binding AChEI potently ameliorates scopolamine-induced cognitive deficits in mice, Pharmacology Biochemistry and Behavior, vol.104, pp.138-143, 2013.
DOI : 10.1016/j.pbb.2012.11.009

A. C. Lo, J. H. De-maeyer, B. Vermaercke, Z. Callaerts-vegh, J. A. Schuurkes et al., SSP-002392, a new 5-HT4 receptor agonist, dose-dependently reverses scopolamine-induced learning and memory impairments in C57Bl/6 mice, Neuropharmacology, vol.85, pp.178-189, 2014.
DOI : 10.1016/j.neuropharm.2014.05.013

K. Madsen, W. Neumann, K. Holst, L. Marner, M. T. Haahr et al., Cerebral serotonin 4 receptors and amyloid-? in early Alzheimer's disease, J. Alzheimers Dis. JAD, vol.26, pp.457-466, 2011.

F. Mao, J. Yan, J. Li, X. Jia, H. Miao et al., New multi-target-directed small molecules against Alzheimer's disease: a combination of resveratrol and clioquinol, Organic & Biomolecular Chemistry, vol.38, issue.31, pp.5936-5944, 2014.
DOI : 10.1016/S0223-5234(03)00012-6

B. Marcos, F. J. Gil-bea, W. D. Hirst, M. García-alloza, and M. J. Ramírez, receptor-mediated acetylcholine release, European Journal of Neuroscience, vol.114, issue.5, pp.1299-1306, 2006.
DOI : 10.1111/j.1460-9568.2006.05003.x

B. Marcos, M. García-alloza, F. J. Gil-bea, T. T. Chuang, P. T. Francis et al., Involvement of an Altered 5-HT6 Receptor Function in Behavioral Symptoms of Alzheimer's Disease, Journal of Alzheimer's Disease, vol.14, issue.1, pp.43-50, 2008.
DOI : 10.3233/JAD-2008-14104

B. Marcos, T. T. Chuang, F. J. Gil-bea, and M. J. Ramirez, Effects of 5-HT6 receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat, British Journal of Pharmacology, vol.3, issue.3, pp.434-440, 2008.
DOI : 10.1007/s00213-003-1683-8

K. Maruyama, Y. Kawamura, H. Asada, S. Ishiura, and K. Obata, Cleavage at the N-Terminal Site of Alzheimer Amyloid ??/A4 Protein Is Essential for Its Secretion, Biochemical and Biophysical Research Communications, vol.202, issue.3, pp.1517-1523, 1994.
DOI : 10.1006/bbrc.1994.2103

K. Matsuzono, T. Yamashita, Y. Ohta, N. Hishikawa, M. Koike et al., Clinical Benefits of Memantine Treatment for Alzheimer???s Disease in the Okayama Memantine Study II (OMS II), Journal of Alzheimer's Disease, vol.350, issue.2, pp.487-493, 2015.
DOI : 10.1007/s00415-006-0374-x

B. R. Matthews, Memory Dysfunction, CONTINUUM: Lifelong Learning in Neurology, vol.21, pp.613-626, 2015.
DOI : 10.1212/01.CON.0000466656.59413.29

K. G. Mawuenyega, W. Sigurdson, V. Ovod, L. Munsell, T. Kasten et al., Decreased Clearance of CNS ??-Amyloid in Alzheimer's Disease, Science, vol.46, issue.6, p.1774, 2010.
DOI : 10.1212/WNL.46.6.1592

R. Mayeux, M. Sano, J. Chen, T. Tatemichi, and Y. Stern, Risk of Dementia in First-Degree Relatives of Patients With Alzheimer's Disease and Related Disorders, Archives of Neurology, vol.48, issue.3, pp.269-273, 1991.
DOI : 10.1001/archneur.1991.00530150037014

A. Meneses, G. Perez-garcia, G. Liy-salmeron, D. Flores-galvez, C. Castillo et al., The effects of the 5-HT6 receptor agonist EMD and the 5-HT7 receptor agonist AS19 on memory formation, Behavioural Brain Research, vol.195, issue.1, pp.112-119, 2008.
DOI : 10.1016/j.bbr.2007.11.023

M. Mesulam, Cholinergic circuitry of the human nucleus basalis and its fate in Alzheimer's disease, Journal of Comparative Neurology, vol.313, issue.Suppl, pp.4124-4144, 2013.
DOI : 10.1002/cne.903130207

N. Mishra, D. Sasmal, and K. K. Singh, Attenuating A??1???42-induced toxicity by a novel acetylcholinesterase inhibitor, Neuroscience, vol.250, pp.309-319, 2013.
DOI : 10.1016/j.neuroscience.2013.07.014

E. S. Mitchell, B. J. Hoplight, S. P. Lear, and J. F. Neumaier, BGC20-761, a novel tryptamine analog, enhances memory consolidation and reverses scopolamine-induced memory deficit in social and visuospatial memory tasks through a 5-HT6 receptor-mediated mechanism, Neuropharmacology, vol.50, issue.4, pp.412-420, 2006.
DOI : 10.1016/j.neuropharm.2005.10.002

E. S. Mitchell, R. A. Mcdevitt, and J. F. Neumaier, Adaptations in 5-HT receptor expression and function: Implications for treatment of cognitive impairment in aging, Journal of Neuroscience Research, vol.41, issue.12, pp.2803-2811, 2009.
DOI : 10.1093/gerona/54.11.B492

E. G. Mohler, S. Shacham, S. Noiman, F. Lezoualc-'h, S. Robert et al., VRX-03011, a novel 5-HT4 agonist, enhances memory and hippocampal acetylcholine efflux, Neuropharmacology, vol.53, issue.4, pp.563-573, 2007.
DOI : 10.1016/j.neuropharm.2007.06.016

I. Molino, L. Colucci, A. M. Fasanaro, E. Traini, and F. Amenta, Efficacy of Memantine, Donepezil, or Their Association in Moderate-Severe Alzheimer???s Disease: A Review of Clinical Trials, The Scientific World Journal, vol.14, issue.2, p.925702, 2013.
DOI : 10.2147/ciia.2006.1.2.143

S. A. Monaco, Y. Gulchina, and W. Gao, NR2B subunit in the prefrontal cortex: A double-edged sword for working memory function and psychiatric disorders, Neuroscience & Biobehavioral Reviews, vol.56, pp.127-138, 2015.
DOI : 10.1016/j.neubiorev.2015.06.022

F. J. Monsma, Y. Shen, R. P. Ward, M. W. Hamblin, and D. R. Sibley, Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs, 1993.

H. Mori, K. Takio, M. Ogawara, and D. J. Selkoe, Mass spectrometry of purified amyloid beta protein in Alzheimer's disease, J. Biol. Chem, vol.267, pp.17082-17086, 1992.

C. Morpurgo, A new design for the screening of CNS-active drugs in mice. A multidimensional observation procedure and the study of pharmacological interactions, 1971.

W. E. Müller, F. J. Romero, S. Perovic, G. Pergande, and P. Pialoglou, Protection of Flupirtine on ??-Amyloid-Induced Apoptosis in Neuronal Cells In Vitro: Prevention of Amyloid-Induced Glutathione Depletion, Journal of Neurochemistry, vol.68, issue.6, pp.2371-2377, 1997.
DOI : 10.1046/j.1471-4159.1997.68062371.x

C. A. Munro, Sex differences in Alzheimer's disease risk: are we looking at the wrong hormones?, International Psychogeriatrics, vol.17, issue.10, pp.1579-1584, 2014.
DOI : 10.1016/S0018-506X(02)00022-3

I. M. Nasrallah and D. A. Wolk, Multimodality Imaging of Alzheimer Disease and Other Neurodegenerative Dementias, Journal of Nuclear Medicine, vol.55, issue.12, 2003.
DOI : 10.2967/jnumed.114.141416

E. Nepovimova, E. Uliassi, J. Korabecny, L. E. Peña-altamira, S. Samez et al., Multitarget Drug Design Strategy: Quinone???Tacrine Hybrids Designed To Block Amyloid-?? Aggregation and To Exert Anticholinesterase and Antioxidant Effects, Journal of Medicinal Chemistry, vol.57, issue.20, 2014.
DOI : 10.1021/jm5010804

O. 'brien, J. T. , M. , and H. S. , Vascular risk factors and Alzheimer's disease, BMC Med, vol.12, p.218, 2014.

H. Oakley, S. L. Cole, S. Logan, E. Maus, P. Shao et al., Intraneuronal beta-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation, Journal of Neuroscience, vol.26, issue.40, pp.10129-10140, 2006.
DOI : 10.1523/JNEUROSCI.1202-06.2006

L. Oberman and A. Leone, Changes in Plasticity Across the Lifespan, Prog. Brain Res, vol.207, pp.91-120, 2013.
DOI : 10.1016/B978-0-444-63327-9.00016-3

D. Obregon, H. Hou, J. Deng, B. Giunta, J. Tian et al., Soluble amyloid precursor protein-?? modulates ??-secretase activity and amyloid-?? generation, Nature Communications, vol.18, p.777, 2012.
DOI : 10.1523/JNEUROSCI.3268-10.2011

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3520614

D. Oliveira, F. F. Bertolucci, P. H. Chen, E. S. Smith, and M. C. , Assessment of risk factors for earlier onset of sporadic Alzheimer???s disease dementia, Neurology India, vol.62, issue.6, pp.625-630, 2014.
DOI : 10.4103/0028-3886.149384

M. Orsetti, A. Dellarole, S. Ferri, and P. Ghi, Acquisition, Retention, and Recall of Memory After Injection of RS67333, a 5-HT4 Receptor Agonist, Into the Nucleus Basalis Magnocellularis of the Rat, Learning & Memory, vol.10, issue.5, pp.420-426, 2003.
DOI : 10.1101/lm.67303

H. Ota, S. Ogawa, Y. Ouchi, and M. Akishita, Protective effects of NMDA receptor antagonist, memantine, against senescence of PC12 cells: A possible role of nNOS and combined effects with donepezil, Experimental Gerontology, vol.72, pp.109-116, 2015.
DOI : 10.1016/j.exger.2015.09.016

M. Pai and W. J. Jacobs, Topographical disorientation in community-residing patients with Alzheimer's disease, International Journal of Geriatric Psychiatry, vol.19, issue.3, pp.250-255, 2004.
DOI : 10.1002/gps.1081

P. K. Panegyres and H. Chen, Earlyonset Alzheimer's disease: a global cross-sectional analysis, Y., and the Coalition against Major Diseases (CAMD), 2014.

V. Parikh, C. S. Bernard, S. X. Naughton, Y. , and B. , Interactions between A?? oligomers and presynaptic cholinergic signaling: Age-dependent effects on attentional capacities, Behavioural Brain Research, vol.274, pp.30-42, 2014.
DOI : 10.1016/j.bbr.2014.07.046

R. Park, S. Kook, J. Park, and I. Mook-jung, A??1???42 reduces P-glycoprotein in the blood???brain barrier through RAGE???NF-??B signaling, Cell Death and Disease, vol.276, issue.6, 1299.
DOI : 10.1097/00001756-199904260-00035

S. Patel, J. A. Grizzell, R. Holmes, R. Zeitlin, R. Solomon et al., Cotinine halts the advance of Alzheimer's disease-like pathology and associated depressive-like behavior in Tg6799 mice, Frontiers in Aging Neuroscience, vol.228, issue.173, p.162, 2014.
DOI : 10.1016/j.bbr.2011.11.023

R. Peñas-cazorla and M. T. Vilaró, Serotonin 5-HT4 receptors and forebrain cholinergic system: receptor expression in identified cell populations, Brain Structure and Function, vol.65, issue.6, pp.3413-3434, 2015.
DOI : 10.1016/0014-4886(79)90255-3

G. Perez-garcía and A. Meneses, Oral administration of the 5-HT receptor antagonists SB-357134 and SB-399885 improves memory formation in an autoshaping learning task, Pharmacology Biochemistry and Behavior, vol.81, issue.3, pp.673-682, 2005.
DOI : 10.1016/j.pbb.2005.05.005

P. Porayette, M. J. Gallego, M. M. Kaltcheva, R. L. Bowen, S. Vadakkadath-meethal et al., Differential Processing of Amyloid-?? Precursor Protein Directs Human Embryonic Stem Cell Proliferation and Differentiation into Neuronal Precursor Cells, Journal of Biological Chemistry, vol.40, issue.35, pp.23806-23817, 2009.
DOI : 10.1016/S0896-6273(02)00604-9

V. F. Prado, H. Janickova, M. A. Onaizi, and M. A. Prado, Cholinergic circuits in cognitive flexibility, Neuroscience, vol.345, 2016.
DOI : 10.1016/j.neuroscience.2016.09.013

A. Quiedeville, M. Boulouard, V. Da-silva-costa-aze, F. Dauphin, V. Bouet et al., 5-HT6 receptor antagonists as treatment for age-related cognitive decline, Reviews in the Neurosciences, vol.25, issue.3, pp.417-427, 2014.
DOI : 10.1515/revneuro-2014-0013

Z. Radak, H. Y. Chung, E. Koltai, A. W. Taylor, and S. Goto, Exercise, oxidative stress and hormesis, Ageing Research Reviews, vol.7, issue.1, pp.34-42, 2008.
DOI : 10.1016/j.arr.2007.04.004

S. Raha, H. J. Lee, S. Yumnam, G. E. Hong, V. V. Saralamma et al., Vitamin D2 suppresses amyloid-? 25-35 induced microglial activation, BV2 cells by blocking the NF-?B inflammatory signaling pathway, 2016.

M. J. Ramirez, M. K. Lai, R. M. Tordera, F. , and P. T. , Serotonergic Therapies for Cognitive Symptoms in Alzheimer???s Disease: Rationale and Current Status, Drugs, vol.10, issue.4, pp.729-736, 2014.
DOI : 10.2174/1567205011310040007

S. Ring, S. W. Weyer, S. B. Kilian, E. Waldron, C. U. Pietrzik et al., The Secreted ??-Amyloid Precursor Protein Ectodomain APPs?? Is Sufficient to Rescue the Anatomical, Behavioral, and Electrophysiological Abnormalities of APP-Deficient Mice, Journal of Neuroscience, vol.27, issue.29, pp.7817-7826, 2007.
DOI : 10.1523/JNEUROSCI.1026-07.2007

S. Rizzo, A. Tarozzi, M. Bartolini, G. Da-costa, A. Bisi et al., 2-Arylbenzofuran-based molecules as multipotent Alzheimer's disease modifying agents, European Journal of Medicinal Chemistry, vol.58, pp.519-532, 2012.
DOI : 10.1016/j.ejmech.2012.10.045

S. L. Rogers and L. T. Friedhoff, The Efficacy and Safety of Donepezil in Patients with Alzheimer's Disease: Results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial, Dementia and Geriatric Cognitive Disorders, vol.7, issue.6, pp.293-303, 1996.
DOI : 10.1159/000106895

C. Routledge, S. M. Bromidge, S. F. Moss, G. W. Price, W. Hirst et al., receptor antagonist, British Journal of Pharmacology, vol.62, issue.7, pp.1606-1612, 2000.
DOI : 10.1038/sj.bjp.0703457

M. Ruat, E. Traiffort, J. M. Arrang, J. Tardivel-lacombe, J. Diaz et al., A Novel Rat Serotonin (5-HT6) Receptor: Molecular Cloning, Localization and Stimulation of cAMP Accumulation, Biochemical and Biophysical Research Communications, vol.193, issue.1, pp.268-276, 1993.
DOI : 10.1006/bbrc.1993.1619

D. Ruzafa, B. Morel, L. Varela, A. I. Azuaga, and F. Conejero-lara, Characterization of Oligomers of Heterogeneous Size as Precursors of Amyloid Fibril Nucleation of an SH3 Domain: An Experimental Kinetics Study, PLoS ONE, vol.71, issue.11, p.49690, 2012.
DOI : 10.1371/journal.pone.0049690.s009

M. M. Ryan, G. P. Morris, B. G. Mockett, K. Bourne, W. C. Abraham et al., Time-dependent changes in gene expression induced by secreted amyloid precursor protein-alpha in the rat hippocampus, BMC Genomics, vol.14, issue.1, p.376, 2013.
DOI : 10.1177/002215549904700311

A. Sambeth, W. J. Riedel, I. Klinkenberg, S. Kähkönen, and A. Blokland, Biperiden selectively induces memory impairment in healthy volunteers: no interaction with citalopram, Psychopharmacology, vol.97, issue.11, pp.1887-1897, 2015.
DOI : 10.1016/j.pneurobio.2012.02.002

B. Schreiner, L. Hedskog, B. Wiehager, and M. Ankarcrona, Amyloid-? peptides are generated in mitochondria-associated endoplasmic reticulum membranes, J. Alzheimers Dis. JAD, vol.43, pp.369-374, 2015.

S. Serino, P. Cipresso, F. Morganti, R. , and G. , The role of egocentric and allocentric abilities in Alzheimer's disease: A systematic review, Ageing Research Reviews, vol.16, pp.32-44, 2014.
DOI : 10.1016/j.arr.2014.04.004

T. J. Shafer and W. D. Atchison, Transmitter, ion channel and receptor properties of pheochromocytoma (PC12) cells: a model for neurotoxicological studies, Neurotoxicology, vol.12, pp.473-492, 1991.

N. Sharma and A. N. Singh, Exploring Biomarkers for Alzheimer???s Disease, JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2016.
DOI : 10.7860/JCDR/2016/18828.8166

F. Shen, J. A. Smith, R. Chang, D. L. Bourdet, P. R. Tsuruda et al., 5-HT4 receptor agonist mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: A pharmacodynamic and pharmacokinetic assessment, Neuropharmacology, vol.61, issue.1-2, pp.69-79, 2011.
DOI : 10.1016/j.neuropharm.2011.02.026

R. M. Shiffrin, Short-term memory: A brief commentary, Memory & Cognition, vol.21, issue.2, pp.193-197, 1993.
DOI : 10.3758/BF03202729

V. Da-silva-costa, P. Duchatelle, M. Boulouard, and F. Dauphin, Selective 5-HT6 Receptor Blockade Improves Spatial Recognition Memory and Reverses Age-Related Deficits in Spatial Recognition Memory in the Mouse, Neuropsychopharmacology, vol.321, issue.2, pp.488-500, 2009.
DOI : 10.1007/s00213-003-1552-5

URL : https://hal.archives-ouvertes.fr/hal-00863265

V. Da-silva-costa, F. Dauphin, and M. Boulouard, Serotonin 5-HT6 receptor blockade reverses the age-related deficits of recognition memory and working memory in mice, Behavioural Brain Research, vol.222, issue.1, 2011.
DOI : 10.1016/j.bbr.2011.03.046

URL : https://hal.archives-ouvertes.fr/hal-00862995

D. Silva-costa-aze, V. Quiedeville, A. Boulouard, M. Dauphin, and F. , 5-HT6 receptor blockade differentially affects scopolamine-induced deficits of working memory, recognition memory and aversive learning in mice, Psychopharmacology, vol.44, issue.2, pp.99-115, 2012.
DOI : 10.1016/j.jpba.2007.02.024

URL : https://hal.archives-ouvertes.fr/hal-00862409

G. ?imi?, M. Babi?-leko, S. Wray, C. R. Harrington, I. Delalle et al., Monoaminergic neuropathology in Alzheimer???s disease, Progress in Neurobiology, vol.151, 2016.
DOI : 10.1016/j.pneurobio.2016.04.001

G. W. Small, P. V. Rabins, P. P. Barry, N. S. Buckholtz, S. T. Dekosky et al., Diagnosis and Treatment of Alzheimer Disease and Related Disorders, Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society, pp.1363-1371, 1997.
DOI : 10.1001/jama.1997.03550160083043

C. M. Smith and M. Swash, Possible biochemical basis of memory disorder in Alzheimer disease, Annals of Neurology, vol.2, issue.6, pp.471-473, 1978.
DOI : 10.1001/archneur.1977.00500160029004

H. Sohanaki, T. Baluchnejadmojarad, F. Nikbakht, and M. Roghani, Pelargonidin Improves Passive Avoidance Task Performance in a Rat Amyloid Beta25-35 Model of Alzheimer's Disease Via Estrogen Receptor Independent Pathways, Acta Med. Iran, vol.54, pp.245-250, 2016.

S. Söllvander, E. Nikitidou, R. Brolin, L. Söderberg, D. Sehlin et al., Accumulation of amyloid-?? by astrocytes result in enlarged endosomes and microvesicle-induced apoptosis of neurons, Molecular Neurodegeneration, vol.58, issue.1, p.38, 2016.
DOI : 10.1002/ana.20524

J. Steffener, A. M. Brickman, B. C. Rakitin, Y. Gazes, and Y. Stern, The Impact of Age-Related Changes on Working Memory Functional Activity, Brain Imaging and Behavior, vol.14, issue.10, pp.142-153, 2009.
DOI : 10.1212/WNL.37.2.179

D. Storga, K. Vrecko, J. G. Birkmayer, and G. Reibnegger, Monoaminergic neurotransmitters, their precursors and metabolites in brains of Alzheimer patients, Neuroscience Letters, vol.203, issue.1, pp.29-32, 1996.
DOI : 10.1016/0304-3940(95)12256-7

V. Strauss, E. Viitanen, M. De-ronchi, D. Winblad, B. Fratiglioni et al., Aging and the Occurrence of Dementia, Archives of Neurology, vol.56, issue.5, pp.587-592, 1999.
DOI : 10.1001/archneur.56.5.587

D. Strooper and B. , Aph-1, Pen-2, and Nicastrin with Presenilin Generate an Active ??-Secretase Complex, Neuron, vol.38, issue.1, pp.9-12, 2003.
DOI : 10.1016/S0896-6273(03)00205-8

G. T. Sutherland, B. Chami, P. Youssef, and P. K. Witting, Oxidative stress in Alzheimer's disease: Primary villain or physiological by-product?, Redox Report, vol.5, issue.2, pp.134-141, 2013.
DOI : 10.3233/JAD-2010-1390

K. Tagawa, T. Kunishita, K. Maruyama, K. Yoshikawa, E. Kominami et al., Alzheimer's disease amyloid ??-clipping enzyme (APP secretase): Identification, purification, and characterization of the enzyme, Biochemical and Biophysical Research Communications, vol.177, issue.1, pp.377-387, 1991.
DOI : 10.1016/0006-291X(91)91994-N

S. Tanaka, S. Nakamura, K. Ueda, M. Kameyama, S. Shiojiri et al., Three types of amyloid protein precursor mRNA in human brain: Their differential expression in Alzheimer's disease, Biochemical and Biophysical Research Communications, vol.157, issue.2, pp.472-479, 1988.
DOI : 10.1016/S0006-291X(88)80273-0

Y. Tanaka, K. Meguro, S. Yamaguchi, H. Ishii, S. Watanuki et al., Decreased striatal D2 receptor density associated with severe behavioral abnormality in Alzheimer???s disease, Annals of Nuclear Medicine, vol.31, issue.2, pp.567-573, 2003.
DOI : 10.1212/WNL.55.2.205

R. E. Tanzi, J. F. Gusella, P. C. Watkins, G. A. Bruns, P. St-george-hyslop et al., Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus, Science, vol.235, issue.4791, pp.880-884, 1987.
DOI : 10.1126/science.2949367

P. N. Tariot, M. R. Farlow, G. T. Grossberg, S. M. Graham, S. Mcdonald et al., Memantine Treatment in Patients With Moderate to Severe Alzheimer Disease Already Receiving Donepezil, JAMA, vol.291, issue.3, pp.317-324, 2004.
DOI : 10.1001/jama.291.3.317

A. M. Tata, L. Velluto, C. Angelo, R. , and M. , Cholinergic System Dysfunction and Neurodegenerative Diseases: Cause or Effect?, CNS & Neurological Disorders - Drug Targets, vol.13, issue.7, pp.1294-1303, 2014.
DOI : 10.2174/1871527313666140917121132

C. J. Taylor, D. R. Ireland, I. Ballagh, K. Bourne, N. M. Marechal et al., Endogenous secreted amyloid precursor protein-?? regulates hippocampal NMDA receptor function, long-term potentiation and spatial memory, Neurobiology of Disease, vol.31, issue.2, pp.250-260, 2008.
DOI : 10.1016/j.nbd.2008.04.011

J. Thomas, C. J. Thomas, J. Radcliffe, I. , and C. , Omega-3 Fatty Acids in Early Prevention of Inflammatory Neurodegenerative Disease: A Focus on Alzheimer???s Disease, BioMed Research International, vol.77, issue.4, 2015.
DOI : 10.1136/jnnp-2012-304792

A. Tolppanen, H. Taipale, M. Koponen, P. Lavikainen, A. Tanskanen et al., Cohort profile: the Finnish Medication and Alzheimer's disease (MEDALZ) study, BMJ Open, vol.6, issue.7, 2016.
DOI : 10.1136/bmjopen-2016-012100

A. Tramutola, C. Lanzillotta, M. Perluigi, and D. A. Butterfield, Oxidative stress, protein modification and Alzheimer disease, Brain Research Bulletin, vol.133, 2016.
DOI : 10.1016/j.brainresbull.2016.06.005

N. T. Vagelatos and G. D. Eslick, Type 2 Diabetes as a Risk Factor for Alzheimer's Disease: The Confounders, Interactions, and Neuropathology Associated With This Relationship, Epidemiologic Reviews, vol.35, issue.1, pp.152-160, 2013.
DOI : 10.1093/epirev/mxs012

N. Vaidehi and T. Kenakin, The role of conformational ensembles of seven transmembrane receptors in functional selectivity, Current Opinion in Pharmacology, vol.10, issue.6, pp.775-781, 2010.
DOI : 10.1016/j.coph.2010.09.004

R. Vassar, B. D. Bennett, S. Babu-khan, S. Kahn, E. A. Mendiaz et al., Beta-Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE, Science, vol.286, issue.5440, pp.735-741, 1999.
DOI : 10.1126/science.286.5440.735

R. S. Vest and C. J. Pike, Gender, sex steroid hormones, and Alzheimer's disease, Hormones and Behavior, vol.63, issue.2, 2013.
DOI : 10.1016/j.yhbeh.2012.04.006

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3413783

A. K. Visser, A. Van-waarde, A. T. Willemsen, F. J. Bosker, P. G. Luiten et al., Measuring serotonin synthesis: from conventional methods to PET tracers and their (pre)clinical implications, European Journal of Nuclear Medicine and Molecular Imaging, vol.27, issue.2, pp.576-591, 2011.
DOI : 10.1016/j.jchemneu.2004.02.003

S. J. Webster, A. D. Bachstetter, P. T. Nelson, F. A. Schmitt, V. Eldik et al., Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models, Frontiers in Genetics, vol.45, p.88, 2014.
DOI : 10.1016/j.neuron.2005.01.040

P. J. West, V. R. Marcy, M. J. Marino, and H. Schaffhauser, Activation of the 5-HT6 receptor attenuates long-term potentiation and facilitates GABAergic neurotransmission in rat hippocampus, Neuroscience, vol.164, issue.2, pp.692-701, 2009.
DOI : 10.1016/j.neuroscience.2009.07.061

A. Wimo, L. Jönsson, J. Bond, M. Prince, and B. Winblad, The worldwide economic impact of dementia 2010, Alzheimer's & Dementia, vol.9, issue.1, 2013.
DOI : 10.1016/j.jalz.2012.11.006

O. Wirths, C. Erck, H. Martens, A. Harmeier, C. Geumann et al., Identification of Low Molecular Weight Pyroglutamate A?? Oligomers in Alzheimer Disease, Journal of Biological Chemistry, vol.5, issue.53, pp.41517-41524, 2010.
DOI : 10.1146/annurev.neuro.31.060407.125529

E. H. Wong, G. P. Reynolds, D. W. Bonhaus, S. Hsu, and R. M. Eglen, Characterization of [3H]GR 113808 binding to 5-HT4 receptors in brain tissues from patients with neurodegenerative disorders, Behavioural Brain Research, vol.73, issue.1-2, pp.249-252, 1996.
DOI : 10.1016/0166-4328(96)00106-4

A. Y. Woo, Y. Song, W. Zhu, X. , and R. , -adrenoceptor, British Journal of Pharmacology, vol.75, issue.Suppl. 1, pp.5477-5488, 2015.
DOI : 10.1124/mol.108.052399

URL : https://hal.archives-ouvertes.fr/hal-01405474

S. Woods, N. N. Clarke, R. Layfield, and K. C. Fone, 5-HT6 receptor agonists and antagonists enhance learning and memory in a conditioned emotion response paradigm by modulation of cholinergic and glutamatergic mechanisms, British Journal of Pharmacology, vol.285, issue.2, pp.436-449, 2012.
DOI : 10.1074/jbc.M109.068759

M. L. Woolley, C. A. Marsden, and K. C. Fone, 5-ht6 Receptors, Current Drug Target -CNS & Neurological Disorders, vol.3, issue.1, pp.59-79, 2004.
DOI : 10.2174/1568007043482561

C. Wu, S. Wang, I. Chang, L. , and K. , The Association Between Dementia and Long-Term Use of Benzodiazepine in the Elderly: Nested Case???Control Study Using Claims Data, The American Journal of Geriatric Psychiatry, vol.17, issue.7, pp.614-620, 2009.
DOI : 10.1097/JGP.0b013e3181a65210

Z. G. Xing, G. D. Yu, L. Qin, F. Jiang, and W. H. Zhao, Effects and mechanism of lipoic acid on beta-amyloid-intoxicated C6 glioma cells, Genetics and Molecular Research, vol.14, issue.4, pp.13880-13888, 2015.
DOI : 10.4238/2015.October.29.8

S. Yahiaoui, K. Hamidouche, C. Ballandonne, A. Davis, J. S. De-oliveira-santos et al., Design, synthesis, and pharmacological evaluation of multitarget-directed ligands with both serotonergic subtype 4 receptor (5-HT4R) partial agonist and 5-HT6R antagonist activities, as potential treatment of Alzheimer???s disease, European Journal of Medicinal Chemistry, vol.121, pp.283-293, 2016.
DOI : 10.1016/j.ejmech.2016.05.048

J. L. Yakel, Cholinergic receptors: functional role of nicotinic ACh receptors in brain circuits and disease. Pflügers Arch. Eur, J. Physiol, vol.465, pp.441-450, 2013.

Z. Yang and A. Levey, Gender Differences: A Lifetime Analysis of the Economic Burden of Alzheimer's Disease, Women's Health Issues, vol.25, issue.5, pp.436-440, 2015.
DOI : 10.1016/j.whi.2015.06.001

B. A. Yankner, L. R. Dawes, S. Fisher, L. Villa-komaroff, M. L. Oster-granite et al., Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease, Science, vol.245, issue.4916, pp.417-420, 1989.
DOI : 10.1126/science.2474201

M. Yoshioka, M. Matsumoto, H. Togashi, and K. Mori, Central Distribution and Function of 5-ht6 Receptor Subtype in the Rat Brain, Annals of the New York Academy of Sciences, vol.43, issue.1 ADVANCES IN S, p.244, 1998.
DOI : 10.1111/j.1749-6632.1998.tb10201.x

M. Zhang, Z. A. Hughes, E. H. Kerns, Q. Lin, and C. E. Beyer, Development of a liquid chromatography/tandem mass spectrometry method for the quantitation of acetylcholine and related neurotransmitters in brain microdialysis samples, Journal of Pharmaceutical and Biomedical Analysis, vol.44, issue.2, pp.586-593, 2007.
DOI : 10.1016/j.jpba.2007.02.024

Z. Zhang, M. Song, X. Liu, S. Kang, S. Duong et al., Delta-secretase cleaves amyloid precursor protein and regulates the pathogenesis in Alzheimer???s disease, Nature Communications, vol.13, issue.8762, 2015.
DOI : 10.1038/npp.2013.243

Z. Zhang, M. Xie, Y. , and K. , Asparagine endopeptidase is an innovative therapeutic target for neurodegenerative diseases, Expert Opinion on Therapeutic Targets, vol.31, issue.3, pp.1237-1245, 2016.
DOI : 10.1038/jcbfm.2012.126

Z. Zhang, Y. Li, C. T. Ng, and Y. Song, Inflammation in Alzheimer???s Disease and Molecular Genetics: Recent Update, Archivum Immunologiae et Therapiae Experimentalis, vol.6, issue.Pt 11, pp.333-344, 2015.
DOI : 10.1101/gad.6.9.1783

Y. Zheng, J. Wang, D. Li, M. Guo, M. Zhen et al., Wnt / ??-Catenin Signaling Pathway Against A?? Toxicity in PC12 Cells, Neurosignals, vol.24, pp.40-47, 2016.
DOI : 10.1159/000442610

G. Zhong, Y. Wang, Y. Zhang, J. J. Guo, and Y. Zhao, Smoking Is Associated with an Increased Risk of Dementia: A Meta-Analysis of Prospective Cohort Studies with Investigation of Potential Effect Modifiers, PLOS ONE, vol.135, issue.1, 2015.
DOI : 10.1371/journal.pone.0118333.s004

Y. Zhu, K. Xiao, L. Ma, B. Xiong, Y. Fu et al., Design, synthesis and biological evaluation of novel dual inhibitors of acetylcholinesterase and ??-secretase, Bioorganic & Medicinal Chemistry, vol.17, issue.4, pp.1600-1613, 2009.
DOI : 10.1016/j.bmc.2008.12.067

N. Zoheir, D. F. Lappin, and C. J. Nile, Acetylcholine and the alpha 7 nicotinic receptor: a potential therapeutic target for the treatment of periodontal disease?, Inflammation Research, vol.130, issue.2, 2012.
DOI : 10.1007/s00418-008-0455-2